This interview is with Kristin Parker, CEO, Axxelus.
How do you introduce your work as CEO of Axxelus to healthcare leaders who ask what problems you solve in commercialization?
Healthcare organizations do not struggle because they lack innovation. They struggle because great solutions often fail to reach the right market, the right buyer, and the right operational use case with enough clarity and speed.
At Axxelus, we help healthcare companies move from promise to adoption. That means sharpening positioning, identifying the real decision-makers, building commercial strategies that reflect how healthcare actually buys, and creating messaging that earns trust across clinical, operational, financial, and executive audiences.
Commercialization in healthcare is not just about sales. It is about credibility, timing, workflow fit, confidence in compliance, and measurable value. My role is to help teams connect those pieces so their solutions are not just understood, but adopted.
What pivotal experiences led you from teaching first grade to leading a healthcare contract sales organization within staffing and recruiting?
My experience as a first-grade teacher shaped the foundation of how I lead today. Teaching required patience, communication, adaptability, empathy, and the ability to manage many moving parts at once while keeping people motivated and supported. Those skills became incredibly valuable as I transitioned into business leadership.
As I moved into staffing, recruiting, and healthcare sales, I quickly recognized many of the same human dynamics at play. Healthcare organizations are under constant pressure to find the right people, support overwhelmed teams, maintain operational stability, and ultimately ensure patients receive quality care.
What drew me to healthcare staffing was the opportunity to solve meaningful problems at scale. I saw how the right talent, the right partnerships, and the right leadership could directly impact organizational performance, team morale, and patient outcomes.
Over time, I combined my strengths in communication, relationship-building, leadership, and strategic growth to help healthcare organizations navigate staffing and operational challenges more effectively. That journey ultimately became the foundation for my work as a CEO and for building a company centered on integrity, service, and long-term partnership.”
You champion “relational sales” over volume tactics—what is one operational change that most transformed outcomes for your outsourced teams?
The biggest operational shift was moving from activity-first sales management to intelligence-led relationship development.
Many outsourced teams are measured almost entirely by volume: more calls, more emails, more touches. Activity matters, but in healthcare, volume without relevance can damage trust quickly. We changed the model by focusing on account intelligence, buyer context, stakeholder mapping, and message quality before outreach began.
That meant our teams were no longer just contacting prospects. They were entering conversations with a clear understanding of the organization’s pressures, the buyer’s priorities, and the value story that would matter most.
The result is better conversations, shorter learning curves, stronger pipeline quality, and more durable client relationships. Relational sales does not mean slow sales. When done correctly, it creates momentum because trust accelerates decision-making.
Staying with team-building, when hiring field teams for high‑science products, what candidate screening or onboarding practice has proven most critical to earning physician trust?
The most important practice is screening for learning agility and executive presence, not just prior sales experience.
In high-science healthcare environments, physicians can tell quickly whether someone understands the clinical context or is simply repeating a script. A strong field representative must be able to absorb complex information, ask thoughtful questions, respect the physician’s expertise, and communicate value without overstating claims.
Onboarding must go beyond product training. It should include:
- clinical scenario practice
- objection handling
- compliance guardrails
- competitive context
- role-play that reflects real physician conversations
Representatives need to understand not only what the product does, but why it matters in the workflow and how it supports better decisions.
Physician trust is earned through preparation, humility, accuracy, and consistency.
Turning to partnerships, what first step do you take to initiate a durable relationship with a health system or IDN that leads to measurable adoption and revenue?
The first step is alignment before the pitch.
Before introducing a solution, I want to understand the health system’s strategic priorities, operating pressures, and internal decision path. Is the organization focused on access, workforce stabilization, margin improvement, quality metrics, patient engagement, risk adjustment, specialty growth, or technology consolidation? The answer changes everything.
Durable partnerships are built when both sides can see a shared business case. That means defining the problem clearly, identifying the stakeholders who must be involved, and agreeing on what success will look like before implementation begins.
Revenue follows adoption, and adoption follows alignment. When the first conversation is centered on the health system’s goals rather than the vendor’s offering, the relationship has a much stronger foundation.
On market access, can you share a time payer or formulary dynamics threatened a launch and the specific adjustment you made to protect growth?
A common challenge in healthcare launches is the assumption that clinical value alone will drive adoption. In reality, payer coverage, formulary status, reimbursement pathways, and administrative burden can either accelerate or stall growth.
When payer or formulary dynamics create friction, the adjustment I make is to refine the commercial strategy around access realities rather than pushing the same message harder. This may mean segmenting accounts by coverage opportunity, equipping field teams with clearer access language, strengthening provider education around patient pathways, or shifting early focus toward markets where reimbursement conditions support adoption.
The key is to avoid treating access as a back-end issue. It has to be built into launch planning, targeting, messaging, and field execution from the start. Protecting growth often comes down to helping teams sell the full pathway, not just the product.
For an early‑stage MedTech or diagnostics company engaging a CSO, what does your first 90 days look like to validate the ideal customer profile and messaging?
The first 90 days should be disciplined, evidence-driven, and fast-moving.
In the first phase, I focus on discovery: reviewing the company’s current positioning, market assumptions, competitive landscape, clinical value proposition, buyer personas, and sales materials. I want to understand where the team believes the opportunity is and where the market is actually responding.
Next, we validate. That includes testing messaging with target accounts, listening carefully to objections, identifying which stakeholders engage, and determining whether the strongest value driver is clinical, operational, financial, strategic, or some combination of these.
By the end of 90 days, the company should have a clearer ideal customer profile, sharper buyer segmentation, stronger talk tracks, more accurate pipeline assumptions, and a field strategy that reflects real-world feedback. The goal is not just activity; it is learning that improves conversion.
When growth opens the door to new segments, how do you decide when and how to expand a successful motion from one specialty, such as cardiology, into another, such as endocrinology?
Expansion should happen when the original motion has enough proof, repeatability, and operational capacity to support the next segment.
I look at several factors:
- whether the clinical problem translates
- whether the economic buyer is similar
- whether the workflow is comparable
- whether the evidence base is strong enough for the new audience
- whether the sales team can credibly speak to the specialty’s unique priorities
A mistake companies make is assuming success in one specialty automatically transfers to another. It rarely does without adaptation. Cardiology and endocrinology may share some patient populations, but the clinical conversations, referral patterns, decision triggers, and value messages can be very different.
The right approach is to protect the core business while testing the new segment in a controlled way. Build specialty-specific messaging, validate the buyer journey, learn from early adopters, and expand when the data supports it.
To sustain momentum, what cadence and feedback loops help your remote, HIPAA‑aware teams build provider relationships at scale without losing compliance or quality?
Remote teams need structure, visibility, and accountability without becoming robotic.
The cadence I like includes:
- Weekly pipeline reviews
- Regular call coaching
- Message testing
- Compliance refreshers
- Rapid feedback loops from the field
Teams should share what they are hearing from providers, which objections are appearing, where messaging is landing, and where additional support is needed.
For HIPAA-aware teams, quality control is essential. That means:
- Clear documentation standards
- Compliant communication practices
- Approved messaging
- Ongoing reinforcement of what can and cannot be discussed
At scale, the goal is consistency without losing personalization. The best remote teams know the guardrails, understand the audience, and have enough market intelligence to make each interaction relevant. Compliance protects the relationship. Quality helps it grow.
Thanks for sharing your knowledge and expertise. Is there anything else you’d like to add?
Healthcare commercialization is changing rapidly. Organizations are facing workforce strain, budgetary pressure, AI-driven disruption, evolving buyer expectations, and an increasingly crowded marketplace. In that environment, clarity matters more than ever.
The companies that succeed will not simply be those with the best technology or the loudest message; they will be those that understand the healthcare ecosystem deeply, build trust across stakeholders, and connect their value to measurable outcomes.
That is the work I care most about: helping healthcare organizations and innovators move with focus, integrity, and commercial discipline, so that good solutions can reach the people and systems that need them.